cyrilzakka/clinical-trials huggingface dataset:
Medtronic MiniMed Implantable Insulin Pump

This research is being done to find out whether subjects previously treated with the implantable insulin pump (IIP) therapy, and now taking insulin by injection, will benefit from re-implantation of IIP. The investigators will see if IIP causes more stable control of blood sugar, with fewer highs and lows. People with type 1 diabetes previously implanted with the MiniMed Implantable Pump (MIP) model 2000 at Johns Hopkins may join this study.

If the participant joins the study and chooses to have a new pump implanted, the study is expected to last 12-15 months for each participant, and each participant will continue to be followed, with 3-monthly refills and research visits for as long as the pump lasts, until the participant chooses to withdraw, until the FDA approves the pump for regular care, or until the company stops supporting the pump. During the first 12-15 months of the study, there will be an estimated 13 clinic visits and one hospital stay for 2-3 days. The data collection visits will take about 30 minutes, and a continuous glucose monitor will be started. The participants will have a brief visit 3-4 days later to drop off the monitor. After this phase of the research, the participants will still be cared for with the implanted pump, having visits for refills and tests every 3 months. This long-term follow up will last until the participants choose to withdraw, the pump malfunctions, the FDA approves the pump for regular care, or the company no longer supports the pump. If the participants are no longer taking part in the study, the investigators will have the pump removed from their body.

Eligibility Criteria:
Inclusion Criteria:

* People with type 1 diabetes previously implanted with the MiniMed Implantable Pump model 2000 at Johns Hopkins may join this study.

Exclusion Criteria:

* Anyone not previously implanted with the MiniMed Implantable Pump model 2000 at Johns Hopkins.
Study Evaluating SCA-136 Tolerability With Dose Titration and Food

To evaluate whether the tolerability of SCA-136 is improved by dosing with food or by increasing dose amounts in a step-wise fashion.


Eligibility Criteria:
Inclusion Criteria:

* Healthy men or women, aged 18 to 50 years

Exclusion Criteria:

* Abnormal vital signs, ECG, or lab results
Early-start Exercise Training in Subacute Heart Failure

The purpose of this study is to evaluate the feasibility and the short-term effects of an early-start aerobic exercise training program on functional capacity, symptoms and neurohormonal activation in chronic heart failure patients with recent acute hemodynamic decompensation.

Prescription of aerobic exercise training in stable chronic heart failure patients finds an evidence-based justification in the acknowledged long-term positive effects of aerobic exercise training on both functional capacity and prognosis in this population. In recent time, evidence has accumulated in normal subjects about short-term favorable effects of aerobic exercise training on sympatho-vagal balance and flow-mediated vasodilation, two physiological mechanisms known to be profoundly altered in the setting of acute hemodynamic decompensation of chronic heart failure. The possible extension of aerobic exercise training indication to chronic heart failure patients admitted for recent acute hemodynamic decompensation not stabilized as yet, may thus provide a valuable, low-cost tool to effectively manage such a high-risk and resource-absorbing population.

Eligibility Criteria:
Inclusion Criteria:

* history of chronic heart failure for at least 6 months, with ongoing acute decompensation defined as onset or worsening of heart failure signs and/or symptoms during the previous 15 days with need of intravenous diuretic and/or vasodilator therapy;
* age \>18 years
* left ventricular ejection fraction \<40%
* proBNP \>1000 pg/ml at admission

Exclusion Criteria:

* ongoing cardiogenic shock
* need of intravenous inotropic therapy
* acute coronary syndrome during the preceding 3 months
* clinical and/or instrumental evidence of myocardial ischemia and/or life-threatening arrhythmias
* previous cardiac valve surgery
* creatinine \>2.5 mg/dl at admission
* severe comorbidities limiting functional capacity
Carpal Tunnel Syndrome in Pregnant Women

The purpose of our study is to evaluate the effectiveness of the home exercise program in patients who develop Carpal tunnel syndrome (CTS).

Materials and Method: Thirty-three patients with CTS (mild to moderate) were included to randomized, single-blind, controlled clinical trial. Based on EMG results and clinical examination, patient group was divided two part as mild and moderate CTS (group 1) and normal (group 2). The Sick Boston Carpal Tunnel Syndrome Questionnaire form was filled in face-to-face method.

Cases in this study: Patients who had pain and numbness problems at the hands of the Bezmiâlem Vakif University Polyclinic for Women and Obstetrics were then directed to the Bezmiâlem Vakif University Physical Therapy Rehabilitation Policlinic. After the examination and clinical testing of each patient (Tinel test, Phalen's test, Reverse Phalen's and Durkan's Carpal Compression test), the patients were directed to Bezmiâlem Vakif University Neurology Policlinic. Based on electromyography (EMG) results and clinical examination, the group was classified as mild and moderate CTS (group 1) and normal (group 2). A disease exercise form was distributed for all patients to do exercises.

Eligibility Criteria:
Inclusion Criteria:

* Provocation tests during the examination and physical examination to match the median nerve distribution those who have symptoms of numbness, tingling, weakness and pain in the hands that have lasted at least 1 month.
* Patients with confirmed mild-moderate idiopathic CTS on EMG.

Exclusion Criteria:

* Previously undergone carpal tunnel surgery
* Gestational diabetes mellitus,
* Eclampsia, preeclampsia
* Thyroid disorders
* Arthropathies
* Hand or wrist trauma
* Bilateral fractures
* Severe cts
* Atrial fibrillation
* Cervical radiculopathy
* Peripheral neuropathy
* Thoracic outlet syndrome
* Diabetes mellitus
* Hypothyroidism
* Hyperthyroidism
* Rheumatologic disease
Integrated Exercise Program in Opioid Agonist Therapy Clinics

Background: Drug use is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. Particular people with opioid dependence have high morbidity and reduced quality of life. A reduction in fitness level for people with substance use disorder reduces the general health and quality of life. Physical activity is recommended as an adjunctive treatment for people with substance use disorder. Due to its positive effects on health, quality of life and substance use. There is minimal evidence from well-controlled randomised trials among people receiving opioid agonist therapy. However, studies indicate that exercise could be promising in opioid agonist therapy.

Study design: BAReAktiv is a multicentre randomised controlled trial. The study aims to recruit approximately 225 patients receiving opioid agonist therapy.

Intervention: A 16-week group-based exercise intervention with workouts twice a week. The exercise program will consist of endurance and strength training. The intervention will be integrated into outpatient's clinics in Bergen and Stavanger, Norway.

Study population: The target group will be patients over 18 years of age with severe opioid use disorder receiving OAT in outpatient clinics.

Expected outcome: This study will inform the relative advantages and disadvantages of an integrated exercise program as an adjunctive treatment. Both physical and mental health outcomes are of interest. Further scale-up will be considered if the provided exercise program is safe and effective.

See below each section

Eligibility Criteria:
Inclusion Criteria:

* Receiving OAT from an included outpatient clinic with follow-up weekly
* Low level of physical activity measured using IPAQ (assessed at screening)
* Confirming interest in participating in physical activity intervention and providing informed consent (criteria specified)
* Giving informed consent

Exclusion Criteria:

* Not able to participate in the intervention due to physical disabilities or severe mental disorders
* Being imprisoned or in inpatient treatment settings
Efficacy of Sublingual Immunotherapy in Polysensitized Allergic Rhinitis Patients

Recently, interest has increased in sublingual immunotherapy (SLIT) for treating allergic rhinitis. It is often suggested that polysensitized patients might not benefit from specific immunotherapy as much as monosensitized patients, although further research on this subject is needed. This study compared the efficacy of SLIT with standardized house dust mite extract in mono- and polysensitized allergic rhinitis patients.

Patients who were sensitized to house dust mites and treated with SLIT for house dust mites for at least 1 year between November 2007 and March 2010 were included. The mono-allergen sensitized group (Mgr) was defined as the patients who were sensitized to Dermatophagoides pteronyssinus (Dp) or D. farinae (Df; n = 70). The poly-allergen sensitized group (Pgr) was defined as the patients who were simultaneously sensitized to house dust mites and other allergens (n = 64). A standardized extract of house dust mites was used for immunotherapy. Anti-allergic medication and the total nasal symptom score (TNSS), including rhinorrhea, sneezing, nasal obstruction, and itchy nose, were evaluated before and 1 year after SLIT.

This study enrolled 134 patients. The TNSS improved significantly after SLIT in both groups, while the change in the TNSS did not differ significantly between the groups. The anti-allergic medication scores also decreased significantly in both groups, but there was no significant difference between the groups.

In polysensitized allergic rhinitis patients, SLIT for Dp/Df gave comparable improvements in both nasal symptoms and rescue medication scores to those in monosensitized patients, regardless of other positive allergens. SLIT for Dp/Df might be considered in polysensitized allergic rhinitis patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients who had sneezing, itching, rhinorrhea, and nasal congestion with or without eye symptoms
* patients who were sensitized to Dermatophagoides pteronyssinus (Dp) or D. farinae (Df), as confirmed by skin prick testing (A/H ratio ≥ 1) or MAST

Exclusion Criteria:

* Patients who had immunotherapy in the preceding 3 years
* Patients who had systemic immunological disorders
Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis

This pilot RCT study is to examine the comparative effectiveness of two decision aids for hip and knee osteoarthritis.

This pilot RCT study is to examine the comparative effectiveness of two decision aids for hip and knee osteoarthritis. The vendors employ different design features (e.g. use of video for patient narratives, interactive values clarification exercise) and the study will examine the relative impact of the different features on decision quality. Eligible subjects will be randomly assigned to receive one of two decision aids before their upcoming clinic visit with a participating provider. Immediately before the visit, participants will complete a short questionnaire about the decision aid. This pilot study will assist with determining the potential difference between these two decision aids on improving knowledge and use of decision aids.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of either hip or knee osteoarthritis
* Scheduled visit with participating orthopedic surgeon

Exclusion Criteria:

* Prior partial or total knee or hip replacement surgery
* Hip fracture or aseptic necrosis in the last 12 months
* Rheumatoid arthritis or psoriatic arthritis
* Unable to read or speak English
Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other molecules (neurotransmitters) attach during the normal every-day workings of the brain. Drugs can bind to those receptor molecules as well. Recent evidence suggests that kappa opioid receptors (KOR's) may play an important role in alcohol drinking behavior. This study will try to determine if naltrexone's ability to attach to these receptors is related to its effectiveness. We will use PET (positron emission tomography) for this study. PET is a type of imaging device found in nuclear medicine. It is used for tracking the presence of injected radioactive materials in the body.


Eligibility Criteria:
Inclusion Criteria:

* Ages 21-50
* Able to read English at 6th grade level or higher and to complete study evaluations
* Regular alcohol drinker

Exclusion Criteria:

* Individuals who are seeking alcohol treatment
* Medical conditions that would contraindicate the use of study medication
* Regular use of other substances
Incidence of Colorectal Cancer in Southwest China: Based on SCC Database

To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China.

The epidemiological feature of colorectal cancer (CRC) showed different trends among countries. Studying the epidemiological and management characteristics between China and the US has important implications for understanding the current status of cancer occurrence, treatment and survival. we established the Southwest China Colorectal (SCC) database, aiming to provide reference information on the diagnosis and management of CRC in China.

Eligibility Criteria:
Inclusion Criteria:

1. Clinical diagnosis of colorectal cancer;
2. Received treatment in medical institutions;
3. Regular follow-up after the diagnosis.

Exclusion Criteria:

Patients who lost to follow-up
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796.

The trial will be conducted in two parts:

* Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH).
* Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).


Eligibility Criteria:
Inclusion Criteria:

1. Participant must be 18 to 80 years of age inclusive
2. Participants who are diagnosed with pulmonary hypertension via right heart catheterisation (RHC), documented at any time prior to Screening.
3. WHO Functional Class II or III
4. Participant has the CardioMEMS PA Sensor implanted.

Exclusion Criteria:

1. Hospital admission related to PH within 3 months prior to Screening.
2. Major surgical procedure within 3 months prior to Screening, unless participant is assessed as completely recovered by the Investigator
3. Diagnosis of PH due to human immunodeficiency virus, portal hypertension, schistosomiasis, or uncorrected congenital heart disease
4. History of left-sided heart disease and/or clinically significant cardiac disease
5. History of uncontrolled systemic hypertension
6. eGFR ≤30 ml/min/1.73m2
7. Life expectancy of \< 12 months, as assessed by the Investigator
8. Diagnosed with a malignancy within 5 years of enrolment
9. Contraindications to protocol-required imaging (MRI), diagnostic, or sampling methods
Effects of Different Doses of Epinephrine on Biomarkers of Nervous System Ischemia-reperfusion Injury in Patients With Stanford Type A Dissection

Aortic dissection is the most common aortic disease leading to death. Among them, patients with Stanford type A dissection (TAAD) are prone to dissection rupture in the early stage, and their condition deteriorates rapidly. They need immediate surgical treatment after admission.In this study, the detection data of biomarkers of nervous system Ischemia / Reperfusion (I/R)injury in patients with Stanford type A dissection were retrospectively analyzed, and the effects of different doses of adrenaline on biomarkers of nervous system I/R injury were evaluated by statistical methods.The information of 132 patients with Stanford type A aortic dissection who underwent sun's operation in the Department of cardiovascular surgery of the first medical center of the PLA General Hospital from January 2012 to January 2019 was retrospectively analyzed.


Eligibility Criteria:
Inclusion Criteria:

* The patient's age was 18-75 years old; TAAD was diagnosed by aortic CTA before operation; Sun's operation was performed within two weeks of onset; Deep hypothermic circulatory arrest (DHCA) and selective unilateral cerebral perfusion via right axillary artery were used for brain protection; Adrenaline was used after operation

Exclusion Criteria:

* Nervous system disease and mental system disease before operation; Recent acute coronary syndrome; Recent cardiac arrest; Recent poor perfusion of visceral or peripheral organs; Recent hypoxemia; Previous history of cardiac surgery; Intraoperative death and death within 48 hours after operation; Neurological or psychiatric symptoms occurred within 48 hours after operation; Adrenaline was not used after operation
Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease

This study is planned to be conducted based on the cohort of patients with severe chronic obstructive pulmonary disease in our hospital. Based on gut microbiota, random forest was used to search for potential diagnostic biomarkers in patients with frequent acute exacerbation and controls with non frequent acute exacerbation; Construct a frequent acute exacerbation risk prediction model using random forest, support vector machine, and BP neural network models. The development of this study will provide valuable references for the clinical classification and prognosis evaluation of chronic obstructive pulmonary disease (COPD), and improve the health level of COPD patients by further searching for treatable targets.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who meet the diagnostic criteria for COPD of the global initiative for chronic obstructive lung diseases (GOLD 2022) and GOLD grading Ⅲ - Ⅳ (FEV1/FVC\&lt;70%, FEV1% predicted value ≤ 50% after Bronchiectasis)
2. Age\&gt;40 years old
3. COPD stable for more than 4 weeks
4. Short acting Bronchiectasis was not used within 24 hours before this experiment, long acting Bronchiectasis was not used within 48 hours, and glucocorticoids were not used throughout the body in the past month
5. Patient informed and signed consent form

Exclusion Criteria:

1. Asthma, active pulmonary tuberculosis, interstitial pneumonia and severe Bronchiectasis
2. Complicated with serious diseases (acute infection, diabetes, stroke, heart disease, liver and kidney dysfunction, cancer or autoimmune disease)
3. History of chronic diarrhea or constipation
4. History of Gastrointestinal Surgery
5. Using probiotics or antibiotics within the past 4 weeks
6. No history of using oral hormones or traditional Chinese medicine in the past three months
7. Pregnancy or lactation
Serum Interleukin - 17A in Juvenile Idiopathic Arthritis

1. This study aims to determine the serum levels of interleukin-17A (IL-17A) in children with juvenile idiopathic arthritis (JIA)
2. Analyze the correlation between IL-17A values and disease activity, certain clinical features, and laboratory markers of inflammation.

Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogenous disorders that manifests as joint inflammation in patients aged \<16 years and lasts longer than 6 weeks. Globally, approximately 3 million children and young adults are suffering from JIA with prevalence rates consistently higher in girls. The prevalence of JIA in Africa and Middle East was observed to be towards the lower range of the global estimate. (1) The precise cause and pathogenesis of JIA are unknown; however, genetic, environmental, and autoimmune factors are hypothesized to play a role in its development. (2) The condition can affect one or more joints and cause systemic symptoms such as fever or rash, as well as extra-articular inflammatory signs such as uveitis.(3)

The IL-17 cytokine superfamily is composed of 6 structurally related cytokines, namely IL-17A-F. The most investigated member of the family is IL-17A. It is synthesized by Th17 cells, γδ-T cells, NK T cells, lymphoid tissue inducer-like cells, Paneth cells, and neutrophils. IL-17A plays important roles in protection from bacterial and fungal infections and in the development of autoimmune diseases (4)

Recently, a number of studies have been conducted on the role of IL-17A in the development of chronic arthritis. It has a role both at the initial stages of joint inflammation and in the destruction of joint cartilage and bone structures.(5) It binds to its receptors on synoviocytes, endothelial cells, fibroblasts and osteoblasts and stimulates production of pro-inflammatory cytokines, chemokines and other inflammatory mediators, and also, interacts synergistically with other pro- inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor alpha.(6)

Eligibility Criteria:
Inclusion Criteria:_ Patients less than 16 years at onset of disease and diagnosed with oligoarticular and polyarticular JIA, fulfilling the ILAR classificationcriteria of JIA.

* Control group will include age-and-sex-matched apparently healthy children.

Exclusion Criteria: • Patients having associated neurological or disabling diseases.

* Patients with diabetes mellitus, acute or chronic infections.
* Patients with another causes of arthritis other than JIA.
The Use of Five-strand Hamstring Autograft to Increase the Graft Size in Anterior Cruciate Ligament Reconstruction - a Prospective Randomized Controlled Trial

Anterior cruciate ligament (ACL) reconstruction is one of most commonly performed orthopaedic surgeries. Several options for graft choice are available and autologous single bundle hamstring graft is most commonly used. Variability exists among patients in terms of hamstring size, and therefore the graft diameter. Recently there has been an increasing amount of literature correlating the hamstring graft diameter with the graft failure rate \[1-4\]. They concluded that graft exceeding 8mm in diameter is associated with a significant lower risk of graft failure. There has been study showing that Asian patients were indeed 'different' from the Caucasians. Ho et al published his findings on Singaporean patients showing that the median graft diameters for female and male patients were 7mm and 8mm respectively \[5\]. A retrospective review our patients undergoing ACL reconstruction in our department over the past 10 years has shown that the mean graft diameter was 7.8mm (range, 5.5-10mm).

The conventional way of four-strand hamstring autograft is done by doubling both the semitendinosus and gracilis tendons to provide a quadrupled graft. Several techniques have been described to increase the size of the hamstring graft. One of those is the -strand hamstring graft, in which the longer semitendinosus tendon is tripled with the shorter gracilis tendon doubled to produce a 5-strand configuration. We hypothesized that the 5-strand hamstring graft would provide a graft of significantly larger diameter than the conventional quadrupled autograft.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-50
* Symptoms and physical examinations consistent with ACL deficiency and magnetic resonance imaging indicating ACL injury

Exclusion Criteria:

* Previous surgeries in the operated knee
* Revision ACL reconstruction
* Contralateral ACL injury
* Concomitant posterior cruciate ligament / collateral ligament surgeries in the operated knee